Revenue
$30.68M
Fiscal year ended 2026-06-30Operating income
$3.87M
Fiscal year ended 2026-06-30Free cash flow
$4.21M
Fiscal year ended 2026-06-30IMMUCELL CORP /DE/ (ICCC) reported revenue of $30.68M and net income of $787.37K for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IMMUCELL CORP /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $30.68M |
| Cost of revenue | $18.31M |
| Gross profit | $12.37M |
| Operating income | $3.87M |
| Net income | $787.37K |
| Research & development | $1.89M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $853.61K |
| Income tax expense | $66.23K |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $8.61M |
| General & administrative | $4.27M |
| Selling & marketing | $4.34M |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $8.86M |
| Total assets | $46.63M |
| Current assets | $21.08M |
| Total liabilities | $15.26M |
| Current liabilities | $4.44M |
| Total equity incl. NCI | $31.37M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $9.08M |
| Accounts receivable | $2.90M |
| Goodwill | $95.56K |
| Long-term debt | $6.80M |
| Accounts payable | Unavailable |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $5.89M |
| Capital expenditures | $1.68M |
| Investing cash flow | -$1.66M |
| Financing cash flow | -$1.37M |
| Net change in cash | $2.86M |
| Stock-based compensation | $554.76K |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $2.42M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $4.21M |
| Gross margin | 40.3% |
| Operating margin | 12.6% |
| FCF margin | 13.7% |
| SBC / revenue | 1.8% |
| Current ratio | 4.75x |
| Revenue YoY growth | Unavailable |
| Net margin | 2.6% |
| R&D / revenue | 6.2% |
| CapEx / revenue | 5.5% |
| Long-term debt / equity | 0.22x |
| Effective tax rate | 7.8% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ICCC in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.